Guy J. Laidig
Impact in
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
- Hematology top 5%
- Multiple Myeloma Research and Treatments
Papers in
-
- Ubiquitin and proteasome pathways 6
- Protein Degradation and Inhibitors 2
- Histone Deacetylase Inhibitors Research 2
- Oncology 4
- Peptidase Inhibition and Analysis 3
- Co-authors
- Mark K. Bennett (8 shared papers)Evan R. Lewis (5 shared papers)Susan D. Demo (7 shared papers)Francesco Parlati (6 shared papers)Jinfu Yang (3 shared papers)Matt I. Gross (1 shared paper)Lijing Chen (1 shared paper)Bindu Goyal (1 shared paper)
- Journals
- Blood (6 papers)Molecular Cancer Therapeutics (1 paper)Tetrahedron Letters (1 paper)Cancer Research (1 paper)
- Partner nations
- United StatesNorway
In The Last Decade
Guy J. Laidig
9 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Cancer Research 653
- Hematology 284
- Biochemistry 125
- Molecular Biology 1.0k
- Oncology 347
Countries citing papers authored by Guy J. Laidig
This map shows the geographic impact of Guy J. Laidig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy J. Laidig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy J. Laidig more than expected).
Fields of papers citing papers by Guy J. Laidig
This network shows the impact of papers produced by Guy J. Laidig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy J. Laidig. The network helps show where Guy J. Laidig may publish in the future.
Co-authors
The 25 scholars most cited alongside Guy J. Laidig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer Hit paper breakdown → | 2014 | 797 |
| 2 | Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Hit paper breakdown → | 2007 | 542 |
| 3 | 1991 | 14 | |
| 4 | 2005 | 13 | |
| 5 | 2008 | 10 | |
| 6 | 2008 | 4 | |
| 7 | 2005 | 2 | |
| 8 | 2007 | 1 | |
| 9 | 2006 | 1 |
About Guy J. Laidig
Guy J. Laidig is a scholar working on Molecular Biology, Oncology, Hematology, Organic Chemistry and Genetics, having authored 9 papers that have together received 1.4k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (6 papers), Multiple Myeloma Research and Treatments (3 papers), Peptidase Inhibition and Analysis (3 papers), Protein Degradation and Inhibitors (2 papers), Histone Deacetylase Inhibitors Research (2 papers), Radical Photochemical Reactions (1 paper), Natural Compounds in Disease Treatment (1 paper) and Cancer, Hypoxia, and Metabolism (1 paper). The work is most often cited by research in Cancer Research (653 citations), Hematology (284 citations), Biochemistry (125 citations), Molecular Biology (1.0k citations) and Oncology (347 citations). Guy J. Laidig has collaborated with scholars based in United States and Norway. Frequent co-authors include Mark K. Bennett, Evan R. Lewis, Susan D. Demo, Francesco Parlati, Jinfu Yang, Matt I. Gross, Lijing Chen, Bindu Goyal, Timothy F. Stanton and Frances Zhao. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Tetrahedron Letters and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.